Sotio LLC

Obsidian Therapeutics Inc, based in Cambridge, MA, is at the forefront of precision cell and gene therapy, utilizing its proprietary cytoDRIVE platform to engineer regulated therapeutic proteins. The company is dedicated to pioneering the next generation of engineered therapeutics to address critical patient needs. With a focus on innovative solutions, Obsidian is advancing its lead clinical program, OBX115, an engineered TIL cell therapy targeting advanced melanoma. The company’s commitment to collaboration and urgency drives its mission to improve patient outcomes through cutting-edge science and technology. Generated from the website

Blueprint Medicines is a pioneering biopharmaceutical company based in Cambridge, MA, dedicated to transforming science into more time for life. With a relentless commitment to accelerating the development of new therapies, they strive to expedite clinical trials and bring approved medicines to patients worldwide, focusing on genomically defined diseases. Their diverse team of passionate individuals thrives on innovation, making bold decisions, and pioneering novel solutions to improve the lives of people with advanced gastrointestinal stromal tumors, systemic mastocytosis, and other diseases. At Blueprint Medicines, they help patients stay one step ahead with precision therapies that adapt to disease evolution, solving for treatment resistance and intractable sites of progression. Their platform is driven by a deep understanding of selective kinase medicines and a discovery engine that sparks innovation. With a commitment to patients, they aim to dramatically improve lives by providing innovative treatments and prolonging benefits through pioneering combinations. Through their clinical programs and pipeline, Blueprint Medicines is dedicated to making a meaningful impact on the lives of patients worldwide.Generated from the website

The Samfund, a program of the Expect Miracles Foundation, is a non-profit organization based in Boston, MA that provides critical financial resources to young adult cancer survivors. Through their Financial Assistance Grants and Family Building Grants, they aim to alleviate the financial burden faced by young adult survivors and support their recovery from the financial impact of cancer. Since 2005, The Samfund has awarded over 2,300 grants totaling more than $3.6 million dollars, addressing the higher rates of financial toxicity experienced by young adult survivors compared to other age groups. By investing in their Innovation and Discovery Funds, which support life-saving cancer research, and EMF's SAMFund, which provides financial assistance, donors can join the fight against cancer and make a life-changing impact on the cancer community.Generated from the website